Among the total of 102 patients, 47 had no successfully obtained rebiopsy sample (31 without progression, 9 with progression before clinical approval of osimertinib, 6 unsuccessful tissue rebiopsies or no targetable lesion, and 1 excluded for sequential osimertinib due to drug-induced pneumonitis caused by prior EGFR TKI). The gene discussed is EGFR; the disease is pneumonitis.